^
    Back
    Association details:
    Biomarker:BCL2/MCL1 ratio elevation
    Cancer:Multiple Myeloma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    1914 Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

    Published date:
    11/03/2022
    Excerpt:
    In this study, we sought to investigate the genomic determinants of response to venetoclax in a real-world setting outside of clinical trials....Our analysis showed a trend towards higher expression of BCL2 (p=0.07) and the BCL2/MCL1 ratio (p=0.07), as well as significant up-regulation of the BCL2/BCL2L1 ratio in patients with higher PFS (p<0.05).
    DOI:
    https://doi.org/10.1182/blood-2022-166572